Position title: TRIP Scientific Manager/Assistant Scientist
Dr. Esbona is the TRIP Laboratory Scientific Manager. Her research focus is in breast cancer inflammatory and tumor microenvironment biomarkers. She has interest in the automated quantitation of standardized histological stains as well as biomarker development. She has expertise with various multiplex IHC/IF techniques and computational imaging analysis.
Jun Wan, Samuel Block, Rebecca Thiry, Karla Esbona, Anjon Audhya and Beth A. Weaver. Mad1 destabilizes p53 by preventing PML from sequestering MDM2. Nature Communications. Submitted October 2018.
Esbona K, Yi Y, Saha S, Yu M, Van Doorn RR, Conklin MW, Graham DS, Wisinski KB, Ponik SM, Eliceiri KW, Wilke LG, Keely PJ. The Presence of Cyclooxygenase 2, Tumor-Associated Macrophages, and Collagen Alignment as Prognostic Markers for Invasive Breast Carcinoma Patients. Am J Pathol. 2018 Mar;188(3):559-573. doi: 10.1016/j.ajpath.2017.10.025. PMID: 29429545
Connor JP, Esbona K, Matkowskyj KA. AKR1B10 expression by immunohistochemistry in surgical resections and fine needle aspiration cytology material in patients with cystic pancreatic lesions; potential for improved nonoperative diagnosis. Hum Pathol. 2017 Dec;70:77-83. doi: 10.1016/j.humpath.2017.10.006. Epub 2017 Oct 24. PMID: 29079172
Esbona K, Inman D, Saha S, Jeffery J, Schedin P, Wilke L, Keely P. COX-2 modulates mammary tumor progression in response to collagen density. Breast Cancer Res. 2016 Mar 22;18(1):35. doi: 10.1186/s13058-016-0695-3. PMID: 27000374